Short Interest in Sera Prognostics, Inc. (NASDAQ:SERA) Declines By 15.1%

Sera Prognostics, Inc. (NASDAQ:SERAGet Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 198,900 shares, a decrease of 15.1% from the April 15th total of 234,400 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 192,000 shares, the days-to-cover ratio is presently 1.0 days.

Sera Prognostics Trading Down 1.7 %

SERA stock opened at $9.10 on Tuesday. Sera Prognostics has a 1-year low of $1.52 and a 1-year high of $12.35. The business’s 50 day moving average is $9.68 and its 200-day moving average is $6.89.

Sera Prognostics (NASDAQ:SERAGet Free Report) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). Sera Prognostics had a negative return on equity of 46.35% and a negative net margin of 11,843.79%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. On average, analysts forecast that Sera Prognostics will post -0.94 earnings per share for the current year.

Insider Activity at Sera Prognostics

In related news, insider John J. Boniface sold 4,902 shares of the stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $9.59, for a total value of $47,010.18. Following the completion of the sale, the insider now owns 134,869 shares in the company, valued at $1,293,393.71. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider John J. Boniface sold 24,474 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $9.04, for a total value of $221,244.96. Following the completion of the transaction, the insider now directly owns 139,771 shares of the company’s stock, valued at $1,263,529.84. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John J. Boniface sold 4,902 shares of Sera Prognostics stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $9.59, for a total transaction of $47,010.18. Following the sale, the insider now owns 134,869 shares in the company, valued at approximately $1,293,393.71. The disclosure for this sale can be found here. Insiders sold a total of 116,389 shares of company stock worth $1,091,514 in the last ninety days. 15.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sera Prognostics

Large investors have recently made changes to their positions in the company. StepStone Group LP bought a new position in Sera Prognostics during the 4th quarter valued at about $61,000. Sanders Morris Harris LLC bought a new stake in Sera Prognostics during the 1st quarter worth approximately $174,000. CWM LLC bought a new stake in Sera Prognostics during the 4th quarter worth approximately $242,000. Resource Consulting Group Inc. acquired a new stake in Sera Prognostics during the 4th quarter valued at $265,000. Finally, Vanderbilt University bought a new position in Sera Prognostics in the 4th quarter valued at $284,000. Institutional investors own 54.64% of the company’s stock.

Analysts Set New Price Targets

Separately, William Blair reiterated an “outperform” rating on shares of Sera Prognostics in a research report on Friday.

View Our Latest Analysis on SERA

Sera Prognostics Company Profile

(Get Free Report)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

Further Reading

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.